Research programme: Humabody VH antibody fragment-based therapeutics - Crescendo BiologicsAlternative Names: CB 001 - Crescendo Biologics
Latest Information Update: 30 Sep 2016
At a glance
- Originator Crescendo Biologics
- Class Immunoglobulin fragments
- Mechanism of Action CD3 antigen modulators; Immunomodulators; Neoplasm antigen modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Psoriasis
- Research Cancer